Kronos Bio Stock (NASDAQ:KRON)
Previous Close
$0.78
52W Range
$0.69 - $1.60
50D Avg
$0.91
200D Avg
$1.00
Market Cap
$52.29M
Avg Vol (3M)
$181.20K
Beta
1.79
Div Yield
-
KRON Company Profile
Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib (ENTO), is an orally administered, selective spleen tyrosine kinase inhibitor for acute myeloid leukemia patients. The company planned registrational phase 3 clinical trial of ENTO in combination with induction chemotherapy in acute myeloid leukemia patients with NPM1 mutations. It is also developing KB-0742, an orally bioavailable inhibitor of cyclin dependent kinase 9 for the treatment of MYC-amplified solid tumors, which is in phase 1/2 clinical trial. The company was incorporated in 2017 and is headquartered in San Mateo, California.
KRON Performance
Peer Comparison
| Ticker | Company |
|---|---|
| CCCC | C4 Therapeutics, Inc. |
| GOSS | Gossamer Bio, Inc. |
| NXTC | NextCure, Inc. |
| ADXN | Addex Therapeutics Ltd |
| CRNX | Crinetics Pharmaceuticals, Inc. |
| SPRO | Spero Therapeutics, Inc. |
| LYRA | Lyra Therapeutics, Inc. |
| LYEL | Lyell Immunopharma, Inc. |
| ERAS | Erasca, Inc. |
| CTMX | CytomX Therapeutics, Inc. |
| ASMB | Assembly Biosciences, Inc. |
| LRMR | Larimar Therapeutics, Inc. |
| REPL | Replimune Group, Inc. |
| ACHL | Achilles Therapeutics plc |
| MRUS | Merus N.V. |
| EWTX | Edgewise Therapeutics, Inc. |
| INBX | Inhibrx Biosciences, Inc. |
| CYCN | Cyclerion Therapeutics, Inc. |
| GBIO | Generation Bio Co. |
| NVCT | Nuvectis Pharma, Inc. |